Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of intrathecal tominersen in manifest Huntington's disease
jRCT2080224757Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing Tominersen q8w, Tominersen q16w with alternating placebo and Placebo q8w (3 arms). Started Jul 2019; status: completed.
02
Drugs
tominersen
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on jRCT2080224757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224757.